Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Felipe CouñagoS MontemuiñoM MartinB TaboadaP Calvo-CrespoM P Samper-OtsP AlcántaraJ CoronaJ L López-GuerraM Murcia-MejíaM López-MataJ Jové-TeixidóM ChustV Díaz-DíazL de Ingunza-BarónT García-CañibanoM L CouseloE Del CerroJ MoradiellosS AmorA VarelaM M PuertasI J ThuissardD Sanz-RosaN R de DiosPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2018)
In this sample of patients with stage IIIA-N2 NSCLC treated with CRTS, 5-year survival (both OS and PFS) was approximately 50%. After CRTS, the patients with the best prognosis were those whose primary tumour and/or mediastinal nodal metastases were downstaged after induction therapy and those who underwent lobectomy. These findings provide further support for neoadjuvant therapy followed by surgery in selected patients.
Keyphrases
- prognostic factors
- lymph node
- rectal cancer
- minimally invasive
- end stage renal disease
- newly diagnosed
- small cell lung cancer
- locally advanced
- coronary artery bypass
- prostate cancer
- chronic kidney disease
- ejection fraction
- neoadjuvant chemotherapy
- coronary artery disease
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- mesenchymal stem cells
- bone marrow
- acute coronary syndrome
- advanced non small cell lung cancer
- free survival